Mediastinal Large B-Cell Lymphoma
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Mediastinal Large B-cell Lymphoma is an early-stage landscape with 10 programs across 7 companies. The most active players are Eastern Cooperative Oncology Group, Gynecologic Oncology Group, German Society for Pediatric Oncology and Hematology GPOH gGmbH. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Eastern Cooperative Oncology Group
2 programs
Gynecologic Oncology Group
1 program
German Society for Pediatric Oncology and Hematology GPOH gGmbH
1 program
Bristol-Myers Squibb
1 program
Amgen
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
60%
Small molecule
6 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.
Analysis
Trial Status
1
clinical trials
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)